Skip to main content
Erschienen in: AIDS and Behavior 7/2023

31.12.2022 | Original Paper

Measuring Oral Pre-exposure Prophylaxis (PrEP) Continuation Through Electronic Health Records During Program Scale-Up Among the General Population in Zambia

verfasst von: Elizabeth Heilmann, Jackson Okuku, Megumi Itoh, Jonas Z. Hines, Jose Tomas Prieto, Mutinta Phiri, Kelvin Watala, Chilufya Nsofu, Melinda Luhana-Phiri, Natalie Vlahakis, Michael Kabongo, Boyd Kaliki, Peter A. Minchella, Bupe Musonda

Erschienen in: AIDS and Behavior | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

HIV pre-exposure prophylaxis (PrEP) is being scaled-up in Zambia, but PrEP continuation data are limited by paper-based registers and aggregate reports. Utilization of Zambia’s electronic health record (EHR) system, SmartCare, may address this gap. We analyzed individuals aged ≥ 15 years who initiated PrEP between October 2020 and September 2021 in four provinces in Zambia in SmartCare versus aggregate reports. We measured PrEP continuation using Kaplan–Meier survival analysis and Cox proportional hazards models. SmartCare captured 29% (16,791/58,010) of new PrEP clients; 49% of clients continued at one month, and 89% discontinued PrEP by February 2022. Women were less likely than men to discontinue PrEP (adjusted hazard ratio [aHR]: 0.89, 95% CI 0.86–0.92, z = − 6.99, p < 0.001), and PrEP clients aged ≥ 50 years were less likely to discontinue PrEP compared to clients 15–19 years (aHR: 0.53, 95% CI 0.48–0.58, z = − 13.04, p < 0.001). Zambia’s EHR is a valuable resource for measuring individual-level PrEP continuation over time and can be used to inform HIV prevention programs.
Literatur
3.
Zurück zum Zitat Republic of Zambia Ministry of Health Directorate of Clinical Care and Diagnostic Services. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2016. Republic of Zambia Ministry of Health Directorate of Clinical Care and Diagnostic Services. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2016.
4.
Zurück zum Zitat Republic of Zambia Ministry of Health. Zambia Consolidated Guidelines for Prevention and Treatment of HIV Infection. 2018. Republic of Zambia Ministry of Health. Zambia Consolidated Guidelines for Prevention and Treatment of HIV Infection. 2018.
5.
Zurück zum Zitat Republic of Zambia Ministry of Health. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2020. Republic of Zambia Ministry of Health. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2020.
10.
Zurück zum Zitat Were D, Musau A, Mutegi J, Ongwen P, Manguro G, Kamau M, et al. Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: results from a programmatic surveillance study. J Int AIDS Soc. 2020;23:e25537.CrossRefPubMedPubMedCentral Were D, Musau A, Mutegi J, Ongwen P, Manguro G, Kamau M, et al. Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: results from a programmatic surveillance study. J Int AIDS Soc. 2020;23:e25537.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Sarr M, Gueye D, Mboup A, Diouf O, Bao MDB, Ndiaye AJ, et al. Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal. Int J STD AIDS. 2020;31:1063–72.CrossRefPubMedPubMedCentral Sarr M, Gueye D, Mboup A, Diouf O, Bao MDB, Ndiaye AJ, et al. Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal. Int J STD AIDS. 2020;31:1063–72.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Kagaayi J, Batte J, Nakawooya H, Kigozi B, Nakigozi G, Strömdahl S, et al. Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda. J Int AIDS Soc. 2020;23:e25588.CrossRefPubMedPubMedCentral Kagaayi J, Batte J, Nakawooya H, Kigozi B, Nakigozi G, Strömdahl S, et al. Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda. J Int AIDS Soc. 2020;23:e25588.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Irungu EM, Mugwanya KK, Mugo NR, Bukusi EA, Donnell D, Odoyo J, et al. Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial. Lancet Glob Health. 2021;9:1730–9.CrossRef Irungu EM, Mugwanya KK, Mugo NR, Bukusi EA, Donnell D, Odoyo J, et al. Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial. Lancet Glob Health. 2021;9:1730–9.CrossRef
14.
Zurück zum Zitat Bärnighausen K, Geldsetzer P, Matse S, Hettema A, Hughey AB, Dlamini P, et al. Qualitative accounts of PrEP discontinuation from the general population in Eswatini. Cult Health Sex. 2021;23:1198–214.CrossRefPubMed Bärnighausen K, Geldsetzer P, Matse S, Hettema A, Hughey AB, Dlamini P, et al. Qualitative accounts of PrEP discontinuation from the general population in Eswatini. Cult Health Sex. 2021;23:1198–214.CrossRefPubMed
15.
Zurück zum Zitat de Dieu Tapsoba J, Zangeneh SZ, Appelmans E, Pasalar S, Mori K, Peng L, et al. Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care. 2021;33:712–20.CrossRefPubMed de Dieu Tapsoba J, Zangeneh SZ, Appelmans E, Pasalar S, Mori K, Peng L, et al. Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care. 2021;33:712–20.CrossRefPubMed
16.
Zurück zum Zitat Ddaaki W, Strömdahl S, Yeh PT, Rosen JG, Jackson J, Nakyanjo N, et al. Qualitative assessment of barriers and facilitators of PrEP use before and after rollout of a PrEP program for priority populations in south-central Uganda. AIDS Behav. 2021;25:3547.CrossRefPubMedPubMedCentral Ddaaki W, Strömdahl S, Yeh PT, Rosen JG, Jackson J, Nakyanjo N, et al. Qualitative assessment of barriers and facilitators of PrEP use before and after rollout of a PrEP program for priority populations in south-central Uganda. AIDS Behav. 2021;25:3547.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Camlin CS, Koss CA, Getahun M, Owino L, Itiakorit H, Akatukwasa C, et al. Understanding demand for PrEP and early experiences of PrEP use among young adults in rural Kenya and Uganda: a qualitative study. AIDS Behav. 2020;24:2149.CrossRefPubMedPubMedCentral Camlin CS, Koss CA, Getahun M, Owino L, Itiakorit H, Akatukwasa C, et al. Understanding demand for PrEP and early experiences of PrEP use among young adults in rural Kenya and Uganda: a qualitative study. AIDS Behav. 2020;24:2149.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Rousseau E, Katz AWK, O’Rourke S, Bekker LG, Delany-Moretlwe S, Bukusi E, et al. Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS ONE. 2021;16:e0258542.CrossRefPubMedPubMedCentral Rousseau E, Katz AWK, O’Rourke S, Bekker LG, Delany-Moretlwe S, Bukusi E, et al. Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS ONE. 2021;16:e0258542.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21:1361–75.CrossRefPubMed Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21:1361–75.CrossRefPubMed
20.
Zurück zum Zitat Mayer CM, Owaraganise A, Kabami J, Kwarisiima D, Koss CA, Charlebois ED, et al. Distance to clinic is a barrier to PrEP uptake and visit attendance in a community in rural Uganda. J Int AIDS Soc. 2019;22:e25276.CrossRefPubMedPubMedCentral Mayer CM, Owaraganise A, Kabami J, Kwarisiima D, Koss CA, Charlebois ED, et al. Distance to clinic is a barrier to PrEP uptake and visit attendance in a community in rural Uganda. J Int AIDS Soc. 2019;22:e25276.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat O’Rourke S, Hartmann M, Myers L, Lawrence N, Gill K, Morton JF, et al. The PrEP journey: understanding how internal drivers and external circumstances impact the PrEP trajectory of adolescent girls and young women in Cape Town, South Africa. AIDS Behav. 2021;25:2154–65.CrossRefPubMedPubMedCentral O’Rourke S, Hartmann M, Myers L, Lawrence N, Gill K, Morton JF, et al. The PrEP journey: understanding how internal drivers and external circumstances impact the PrEP trajectory of adolescent girls and young women in Cape Town, South Africa. AIDS Behav. 2021;25:2154–65.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Jackson-Gibson M, Ezema AU, Orero W, Were I, Ohiomoba RO, Mbullo PO, et al. Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya. BMC Public Health. 2021;21:1–13.CrossRef Jackson-Gibson M, Ezema AU, Orero W, Were I, Ohiomoba RO, Mbullo PO, et al. Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya. BMC Public Health. 2021;21:1–13.CrossRef
23.
Zurück zum Zitat Pintye J, Rogers Z, Kinuthia J, Mugwanya KK, Abuna F, Lagat H, et al. Two-way short message service (SMS) communication may increase pre-exposure prophylaxis continuation and adherence among pregnant and postpartum women in Kenya. Glob Health Sci Pract. 2020;8:55–67.CrossRefPubMedPubMedCentral Pintye J, Rogers Z, Kinuthia J, Mugwanya KK, Abuna F, Lagat H, et al. Two-way short message service (SMS) communication may increase pre-exposure prophylaxis continuation and adherence among pregnant and postpartum women in Kenya. Glob Health Sci Pract. 2020;8:55–67.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Mboup A, Béhanzin L, Guédou FA, Geraldo N, Goma-Matsétsé E, Giguère K, et al. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. J Int AIDS Soc. 2018;21:e25208.CrossRefPubMedPubMedCentral Mboup A, Béhanzin L, Guédou FA, Geraldo N, Goma-Matsétsé E, Giguère K, et al. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. J Int AIDS Soc. 2018;21:e25208.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, et al. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Lancet Child Adolesc Health. 2020;4:875–83.CrossRefPubMedPubMedCentral Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, et al. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Lancet Child Adolesc Health. 2020;4:875–83.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Mujugira A, Nakyanzi A, Nabaggala MS, Muwonge TR, Ssebuliba T, Bagaya M, et al. Effect of HIV self-testing on PrEP adherence among gender-diverse sex workers in Uganda: a randomized trial. J Acquir Immune Defic Syndr (1988). 2022;89:381.CrossRef Mujugira A, Nakyanzi A, Nabaggala MS, Muwonge TR, Ssebuliba T, Bagaya M, et al. Effect of HIV self-testing on PrEP adherence among gender-diverse sex workers in Uganda: a randomized trial. J Acquir Immune Defic Syndr (1988). 2022;89:381.CrossRef
27.
Zurück zum Zitat Cassidy T, Ntuli N, Kilani C, Malabi N, Rorwana B, Mutseyekwa T, et al. Delivering PrEP to young women in a low-income setting in South Africa: lessons for providing both convenience and support. AIDS Behav. 2022;26:147–59.CrossRefPubMed Cassidy T, Ntuli N, Kilani C, Malabi N, Rorwana B, Mutseyekwa T, et al. Delivering PrEP to young women in a low-income setting in South Africa: lessons for providing both convenience and support. AIDS Behav. 2022;26:147–59.CrossRefPubMed
28.
Zurück zum Zitat Claassen CW, Mumba D, Njelesani M, Nyimbili D, Mwango LK, Mwitumwa M, et al. Initial implementation of PrEP in Zambia: Health policy development and service delivery scale-up. BMJ Open. 2021;11:e047017.CrossRefPubMedPubMedCentral Claassen CW, Mumba D, Njelesani M, Nyimbili D, Mwango LK, Mwitumwa M, et al. Initial implementation of PrEP in Zambia: Health policy development and service delivery scale-up. BMJ Open. 2021;11:e047017.CrossRefPubMedPubMedCentral
Metadaten
Titel
Measuring Oral Pre-exposure Prophylaxis (PrEP) Continuation Through Electronic Health Records During Program Scale-Up Among the General Population in Zambia
verfasst von
Elizabeth Heilmann
Jackson Okuku
Megumi Itoh
Jonas Z. Hines
Jose Tomas Prieto
Mutinta Phiri
Kelvin Watala
Chilufya Nsofu
Melinda Luhana-Phiri
Natalie Vlahakis
Michael Kabongo
Boyd Kaliki
Peter A. Minchella
Bupe Musonda
Publikationsdatum
31.12.2022
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 7/2023
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-022-03966-1

Weitere Artikel der Ausgabe 7/2023

AIDS and Behavior 7/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.